The Sims 3: Perfect Genetics Challenge- {Part 7} Talented Toddlers!
Read Me. We spend the entire day teaching the triplets to walk, talk and use the potty! Also, Aden complains about his noisy siblings... a lot. Origi...

By: Moar Sims

Visit link:
The Sims 3: Perfect Genetics Challenge- {Part 7} Talented Toddlers! - Video

Recommendation and review posted by Bethany Smith

The Sims 3: Perfect Genetics Challenge - Ep. 2 1/2

By: simsiguess

More here:
The Sims 3: Perfect Genetics Challenge - Ep. 2 1/2 - Video

Recommendation and review posted by Bethany Smith

The Sims 3 | Perfect Genetics Challenge Part 5: Adios Darren!
In this part, we befriend another man and say bye to lesbian Darren! Backstory: "Once upon a time, the Mighty Player sent a Sim to live in the world where all its creations were living happily....

By: simplyapril

Here is the original post:
The Sims 3 | Perfect Genetics Challenge Part 5: Adios Darren! - Video

Recommendation and review posted by Bethany Smith

Chernobyl TGA genetics
Cali prop 215 medical cannabis collective.

By: xclucifer

Read more:
Chernobyl TGA genetics - Video

Recommendation and review posted by Bethany Smith

How Spouses Are Genetically Similar
Opposites attract... right? Not according to new research! Join Tara as she discusses how most couples are genetically similar, and lists out a few theories as to why this is! Read More: Couples...

By: DNews

See original here:
How Spouses Are Genetically Similar - Video

Recommendation and review posted by Bethany Smith

BEYOND THE BUBBLE: 10 Years of Gene Therapy
10 minute documentary/feature created as my end of year project for my Masters course in TV Journalism at Nottingham Trent University. Made by David Sykes on 15/07/11. Copyright Nottingham...

By: David Sykes

See the original post:
BEYOND THE BUBBLE: 10 Years of Gene Therapy - Video

Recommendation and review posted by Bethany Smith

AChildrens Hospital of Philadelphia spinout with the potential to be the first to win U.S. FDA approval of a gene therapy is now funded through the rest of development of its lead treatment for inherited blindness.

Spark Therapeutics is in the middle of a Phase 3 clinical trial that will determine whether the gene therapy its developed can successfully restore some vision to people with rare degenerative eye diseases caused by mutations in the RPE65 gene. Theres currently no treatmentavailable for these diseases.

To allow Spark to continue that study and prepare for commercialization, the company has just closed an oversubscribed $72.8 million Series B financing. Investors including Sofinnova Ventures, Brookside, Deerfield, Rock Springs Capital, T. Rowe Price, Wellington and CHOP participated.

Developed at CHOPs Center for Cellular and Molecular Therapeutics, the therapy uses a neutralized virus as a vehicle to deliver a function gene to targeted cells in the eye. Once there, it enables production of a critical protein thats missing as a result of a mutation and causes vision loss.

In earlier studies, the company reported that some children who were nearly blind as the result of a RPE65 mutation were able to recognize faces and walk without aid after receiving the treatment.

One major difference between Sparks approach and others under development is that gene therapy has the potential to be a one-time, curative treatment, rather than a treatment patients would need to take for life, said CEO Jeffrey Marrazzo in an email.

The current Phase 3 open-label, randomized, controlled study includes 16 patients who are receiving the therapy through a subretinal injection and eight patients in the control arm. Theyre being monitored for improvements to orientation, mobility, navigational ability and performance on vision tests.

Marrazzo said data is expected in 2015.

In addition to the lead therapy, funding will also support growth in Sparks other gene therapy programs in hemophilia B and other rare diseases.

Although the concept of gene therapy has been around for decades, its only recently advanced to the point where regulatory agencies are acknowledging it as safe and effective enough to approve for sale. A number of companies including Amgen, BlueBird Bio and Advantagene are working toward U.S. approval for gene therapy treatments for cancer or rare diseases.

Read the rest here:
Spark Therapeutics late-stage gene therapy for inherited blindness takes a $73M step forward

Recommendation and review posted by Bethany Smith

AUTOLOGOUS Adipose Stem Cells

Stem Cell Therapy is not a new technology. As a matter of fact it has been around for more that 60 years now. The problem is most people know it as a bone marrow transplant. And well when you finish saying that people are already screaming "That's Painful". A bone marrow transplant essentially extracts stem cells from your own bone marrow and then returns them back to you. It has been used to help people suffering from conditions like Leukemia and Lymph Node Cancer.

How does it work? Stem Cells hone in on "chemokine" signals that are secreted by injury. When they arrive they alert regenerative cells to go to work and repair the damage, or grow tissue.

At birth, the human body has around 80 million active stem cells working. At age 40 we have less than 25 million active stem cells working. Therefore it takes longer for the body to heal and in some cases damage is often ignored. This is the aging or degeneration process of the body.

In 1998 a little known about Bio Tech Company discovered that there was an enormous amount of stem cells in abdominal fat, commonly referred to as Adipose fat. In fact there are about 1-2 million stem cells and regenerative cells in 1 cc of abdominal fat. Bone marrow contains less than 10% of that. The stem cells in the abdomen are in a dormant or inactive state. The challenge lay only in how to activate them.

In early 2000 the problem had been solved. A special separation process was used to isolate stem cells from abdominal fat and a perfected heliotherapy process activated the stem cells. These super-charged stem cells were now ready to go to work healing your body.

Fat Stem Cell Therapy has been used for over a decade now as therapy for a variety of medical problems as well as an alternative to painful cosmetic surgery. Fat Stem Cell Therapy can help patients suffering from medical conditions such as, Osteoarthritis, Pulmonary Disease, and Diabetes Type II, as well as some Cosmetic Procedures like Face Lifts, Breast Augmentation, and Anti-Aging.

Infinite Horizons Medical Center and its association with a leading Bio Tech company are able to deliver these high tech therapies with precision, expertise and a level of care which rivals any in the world. These painless medical procedures uses the clients' own adult stem cells to treat clients' medical problems. The procedures themselves take roughly 3.5 - 7 hours to complete.

The procedure involves extracting autologous adipose stem cells, enriching them, activating the enriched stem cells and finally returning these stem cells back into the clients' body. The procedure only requires a local anesthetic, is 100% safe, 100% effective and there is a 0% chance of rejection. For more detailed information see our procedure page.

Infinite Horizons Medical Center has put together an incredible program for clients in search of medical treatment with fat stem cell therapy for, Pulmonary Disorders, like IPF or COPD, Diabetes Type II and Osteoarthritis. It has also put together special programs with fat stem cell therapy for cosmetic procedures like Anti-Aging, Breast Augmentation and Face Lifts.

Link:
Fat Stem Cell Therapy | Medical Treatments Cosmetic Procedures

Recommendation and review posted by simmons

Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into stem cell therapeutics and regenerative therapies, including animal models and clinical trials. The journal also provides reviews, viewpoints, commentaries and reports.

There has been an error retrieving the data. Please try again.

Immortalization of adipose-derived stromal cells

Immortalized human adipose-derived stromal cells maintain most of their original mesenchymal features, in particular the capability to produce significant amounts of angiogenic factors, with potential advantages for laboratory research and regenerative medicine.

Markers of cellular aging in cultured MSCs

Specific gene markers which distinguish aging multipotent stromal cells (MSCs) grown in culture are identified through gene expression profiling using microarray technology.

WJ-MSC transplantation in diabetes

Treatment with Whartons jelly mesenchymal stem cells (WJ-MSC) can improve metabolic control and beta cell function in patients with type 2 diabetes mellitus.

Cell-based therapy in ophthalmology

Debashish Das and colleagues review the stem cell populations of the eye and their respective functions in cell-based therapy and regenerative medicine in ophthalmology.

Continued here:
Stem Cell Research & Therapy

Recommendation and review posted by simmons

1st Flight, post Spinal Cord Injury
343 days after my accident I flew from Polipoli on Haleakala, Maui.

By: Justin Boer

Read more from the original source:
1st Flight, post Spinal Cord Injury - Video

Recommendation and review posted by sam

CIRM Movie on Diabetes for Viacyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells...

By: Viacyte

Go here to see the original:
CIRM Movie on Diabetes for Viacyte - Video

Recommendation and review posted by sam

Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell
Dallas hair transplant surgeon, Dr. Sam Lam, speaks at the 5th Brazilian Congress on Hair Restoration, held in Maresias, Brazil, on May 23, 2014, on the subj...

By: Samuel Lam

More:
Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell - Video

Recommendation and review posted by sam

The Spanish start-up Aglaris Cell is close to launching onto the market the world's first bioreactor that cultures cell in a fully automated way, without using toxic additives. The device has attracted interest from the University of Oxford and the pharmaceutical giant, Merk.

David Horna, a 33-year-old from Madrid and one of the co-founders of Aglaris Cell, whose offices are located in the Madrid Scientific Park (PCM), is in London this week to meet with investors to secure a second round of funding. Horna, alongside his two partners, Miquel Costa and Manuel A. Gonzlez de la Pea, created the company a little over two years ago with the aim of developing a device that would automate stem cell cultures thereby making advances in the production of 'live' medicines.

As David Horna explained, after four years of intensive research and development, the prototype called Aglaris Facer 1.0, patented in 2012 in Spain and in the process of obtaining its international patent, "is practically ready to be sold on the market."

The idea of developing this device came about when the partners, who worked in various fields of biotechnology, noticed that more and more industries were using cells and tissues in their production processes.

Fully automatic

"We saw that the way live medicines from stem cells were being produced was highly manual, and so we came up with the idea of designing and developing a cell culture bioreactor that could automate the entire process. We believe that the stem cell-based therapies sector is going to expand rapidly in the years to come and will become a very promising business," Horna stated.

He noted that there are other bioreactors on the market and some have been able to automate some of the stages in the process, "but ours is the first in the world to perform all the process stages in a fully automated way."

Until now, an additive called trypsin was usually used in this type of culture, however, trypsin is toxic for cells and removes part of the membrane's proteins. "It has been used up to now because there was no other alternative, but our technology does not need to use this product," Horna said.

"Instead, our development uses an iterative method of cell culture which enables us to completely automate and remove the need for human involvement in the cell separation and washing stages, without using any additives that increase the toxicity level. We have achieved this by using smart surfaces that make cell adhesion and de-adhesion possible depending on changes in the environment," the co-founder explained.

He also adds that "we are currently finalising the developments that also make it possible to use the same device to produce genetically-modified cell lines for cellular reprogramming and gene therapies." These advances build on the work Horna undertook for his thesis on smart surfaces at the Spanish National Centre for Cardiovascular Research (CNIC) and the Sarri Institute of Chemistry (IQS) which was published in the 'Advanced Healthcare Materials' journal.

View post:
Packaged batches of stem cells for regenerative medicine

Recommendation and review posted by simmons

Dr. J Off Air - SVF Stem Cell Therapy Informational Video
http://www.innovationsstemcellcenter.com Call: 214.420.7970 If you are considering stem cell therapy, you need to watch this video prior to your consultation. Facebook: https://www.facebook.com/i...

By: dallasdrj

Link:
Dr. J Off Air - SVF Stem Cell Therapy Informational Video - Video

Recommendation and review posted by simmons

(PRWEB) May 26, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market. http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire before buying at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download PDF brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48.

A number of factors such as increasing funding from various government and private organizations, growing industry focus on stem cell research, and rising global awareness about stem cell therapies through various organizations are driving the growth of the global market. In addition, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cell therapy are other factors that are propelling the growth of the market.

However, factors such as lack of required infrastructure, ethical issues related to embryonic stem cell, and difficulties related with the preservation of stem cell are restraining the growth of the market.

Go here to read the rest:
Stem Cell Therapy Market Worth $330 Million in 2020 - New Report by MarketsandMarkets

Recommendation and review posted by simmons

A new Israeli company is using the natural process of cell death to help people undergoing transplants of all kinds live longer. This counterintuitive approach is the vision of Cellect and could radically change the way people with leukemia manage their disease.

Stem cells hold the promise to eradicate cancer and other devastating diseases. But one of the biggest bottlenecks for clinicians and researchers is getting enough stem cells in a blood sample to use in transplantation.

If too many of the donors regular body cells are left in the sample, a patient undergoing a bone-marrow transplant will probably suffer an immune reaction, which can be deadly. In fact, about half of all bone-marrow transplants lead to graft vs. host disease, requiring a lifetime of immunosuppressant drugs.

A new approach to harvesting stem cells is required, says Dr. Shai Yarkoni, a medical doctor, biomed expert and co-founder and CEO of Cellect.

Stem cells are defined not by how they look but what they can do. So my partner, Dr. Nadir Askenasy also a physician, a chemist and a genius came up with an intuitive approach for how we should select them from a sample for transplantation, says Yarkoni in an interview with ISRAEL21c.

Off-the-shelf, cheaper, faster

Several companies, such Miltenyi Biotec in Germany, make tools to cull stem cells from donor blood. But the process is expensive, about $50,000 per transplant, and requires three days of work by skilled personnel. Worse, the current technology still leaves a significant amount of body cells behind or alternatively, too few stem cells.

Thousands of companies and millions of researchers know what they can do with stem cells, but the raw material is the critical issue, Yarkoni says. How do you get enough stem cells to start the treatment?

Cellects stem-cell selection kit, a unique medical device originally conceived by Askenasy about a decade ago, could accomplish the task more effectively, and for a fraction of the cost.

The only tool thats needed is a biological hood, and these can be found even in developing countries. The process takes less than 10 hours and its simple to do, based on the natural process of cell death (apoptosis).

Read more:
Israeli stem-cell technology targets leukemia | ISRAEL21c

Recommendation and review posted by Bethany Smith

By Traci Pedersen Associate News Editor Reviewed by John M. Grohol, Psy.D. on May 25, 2014

Neurons generated from the skin cells of schizophrenia patients behave strangely in the early developmental stages, offering clues that might lead to earlier detection and treatment, according to scientists from the Salk Institute.

The study, published in the journal Molecular Psychiatry, supports the theory that the neurological dysfunction that eventually leads to schizophrenia may begin in the brains of fetuses.

This study aims to investigate the earliest detectable changes in the brain that lead to schizophrenia, said Fred H. Gage, Ph.D., professor of genetics at Salk. We were surprised at how early in the developmental process that defects in neural function could be detected.

Up until now, scientists could only study the disease by examining the brains of cadavers; but age, stress, medication, or drug abuse had often changed or damaged these brains, making it harder to figure out the where it all began.

The Salk scientists were able to go around this obstacle by using stem cell technologies. They took skin cells from patients, coaxed the cells back to an earlier stem cell form and then prompted them to grow into very early-stage neurons called neural progenitor cells (NPCs). These NPCs are similar to cells found in the brain of a fetus.

The researchers tested the cells in two ways: In one test, they looked at how far the cells moved and interacted with particular surfaces; in the other test, they looked at cell stress by imaging mitochondria, tiny organelles that generate energy for the cells.

On both tests, the NPCs from schizophrenia patients differed in significant ways from those taken from people without the disease.

In particular, cells taken from people with schizophrenia showed unusual activity in two major classes of proteins: those involved in adhesion and connectivity, and those involved in oxidative stress. Schizophrenia neural cells seemed to have aberrant migration (which may result in the poor connectivity seen later in the brain) and greater levels of oxidative stress.

These results support the current theory that eventsduring pregnancy can contribute to schizophrenia, even though symptoms typically dont begin until early adulthood. For example, previous research suggests that pregnant mothers who experience infection, malnutrition, or extreme stress are at greater risk of having children with schizophrenia.

Continue reading here:
Skin Cell Research Suggests Schizophrenia Begins in Womb

Recommendation and review posted by Bethany Smith

2 YEAR NATURAL HAIR JOURNEY (Type 4)
This video is from 2012 to 2014, I used ovation hair cell therapy for my first year and I liked it a lot. I mostly used coconut oil and olive oil. main and tail products and suave naturals....

By: Curly Candy Hair

Read more:
2 YEAR NATURAL HAIR JOURNEY (Type 4) - Video

Recommendation and review posted by Bethany Smith

Stem cell therapy | biopen Copy
http://www.arthritistreatmentcenter.com I #39;m in Australia again... to report on a fascinating new concept when it comes to stem cells. Surgeons 3D print stem cells and repair bone with biopen...

By: Nathan Wei

Continue reading here:
Stem cell therapy | biopen Copy - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

25-May-2014

Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego

Researchers at the University of California, San Diego School of Medicine have identified a mutated gene common to adenosquamous carcinoma (ASC) tumors the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer.

The findings are published in the May 25 advance online issue of Nature Medicine.

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with roughly 45,220 new cases diagnosed and more than 38,400 deaths annually. Both numbers are rising. ASC cases are infrequent, but typically have a worse prognosis than more common types of pancreatic cancer.

"There has been little progress in understanding pancreatic ASC since these aggressive tumors were first described more than a century ago," said co-senior author Miles F. Wilkinson, PhD, professor in the Department of Reproductive Medicine and a member of the UC San Diego Institute for Genomic Medicine. "One problem has been identifying mutations unique to this class of tumors."

In their paper, Wilkinson, co-senior author Yanjun Lu, PhD, of Tongji University in China, and colleagues report that ASC pancreatic tumors have somatic or non-heritable mutations in the UPF1 gene, which is involved in a highly conserved RNA degradation pathway called nonsense-mediated RNA decay or NMD. It is the first known example of genetic alterations in an NMD gene in human tumors.

NMD has two major roles. First, it is a quality control mechanism used by cells to eliminate faulty messenger RNA (mRNA) molecules that help transcribe genetic information into the construction of proteins essential to life. Second, it degrades a specific group of normal mRNAs, including those encoding proteins promoting cell growth, cell migration and cell survival. Loss of NMD in these tumors may "release the brakes on these molecules, and thereby driving tumor growth and spread," said Wilkinson.

###

Link:
Gene mutation found for aggressive form of pancreatic cancer

Recommendation and review posted by Bethany Smith

Crowd marches against genetic engineering of food
Crowd marches against genetic engineering of food.

By: reddingnews

Read more:
Crowd marches against genetic engineering of food - Video

Recommendation and review posted by Bethany Smith

How Genetic Engineering Can Cure Drug Addiction? Michael Crichton on Treatment (2006)
Genetic engineering, also called genetic modification, is the direct manipulation of an organism #39;s genome using biotechnology. New DNA may be inserted in the...

By: Remember This

See the article here:
How Genetic Engineering Can Cure Drug Addiction? Michael Crichton on Treatment (2006) - Video

Recommendation and review posted by Bethany Smith

Object Oriented Programming
In object oriented programming, "Objects" usually refer to bundles of information. For example, you can describe a Car as having #39;number_of_wheels = 4 #39; and #39;license_plate = 4BIUO11 #39;, and this...

By: J. Christopher Anderson

Link:
Object Oriented Programming - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

26-May-2014

Contact: Philippa Walker 44-117-928-8086 University of Bristol

An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.

Researchers at the Universities of Bristol, Mnster and the Lithuanian Institute of Biotechnology have observed the process by which a class of enzymes called CRISPR pronounced 'crisper' bind and alter the structure of DNA.

The results, published in the Proceedings of the National Academy of Sciences (PNAS) today, provide a vital piece of the puzzle if these genome editing tools are ultimately going to be used to correct genetic diseases in humans.

CRISPR enzymes were first discovered in bacteria in the 1980s as an immune defence used by bacteria against invading viruses. Scientists have more recently shown that one type of CRISPR enzyme Cas9 can be used to edit the human genome - the complete set of genetic information for humans.

These enzymes have been tailored to accurately target a single combination of letters within the three billion base pairs of the DNA molecule. This is the equivalent of correcting a single misspelt word in a 23-volume encyclopaedia.

To find this needle in a haystack, CRISPR enzymes use a molecule of RNA - a nucleic acid similar in structure to DNA. The targeting process requires the CRISPR enzymes to pull apart the DNA strands and insert the RNA to form a sequence-specific structure called an 'R-loop'.

The global team tested the R-loop model using specially modified microscopes in which single DNA molecules are stretched in a magnetic field. By altering the twisting force on the DNA, the researchers could directly monitor R-loop formation events by individual CRISPR enzymes.

Here is the original post:
Breakthrough shows how DNA is 'edited' to correct genetic diseases

Recommendation and review posted by Bethany Smith

A level. O.10. Chi squared test and genetics (Ms Cooper)

By: Ms Cooper #39;s Cambridge A level Biology

More here:
A level. O.10. Chi squared test and genetics (Ms Cooper) - Video

Recommendation and review posted by Bethany Smith